Lecture 4-5 Kahoot Flashcards

1
Q

TRUE OR FALSE

An antagonist with a high affinity for a receptor will typically have a high efficacy as well.

A

false

an antagonist with a high affinity for a receptor will typically have a lower(?) efficacy as well.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Antagonists have affinity but _____ efficacy

A

zero/low

Antagonists have affinity but zero intrinsic efficacy; they bind to target receptor but produce no response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

A drug with a large dissociation constant (kd) value for a receptor has _______ affinity for the receptor.

A

low

a drug with a large dissociation constant (kd) value for a receptor has LOW affinity for the receptor.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

which of the following drugs has the highest potency?

A

curve C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What determines a drug having high potency?

A

a more potent drug requires a lower concentration to give a specified percentage response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

A _________ dose-response curve measures the effectiveness of a drug within a population.

A

quantal

a quantal-dose response curve plots fraction of a population that responds to a given dose of a drug…

is the effect present/not present

frequency of effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is ED50?

A

dose required to produce a therapeutic effect in 50% of the population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which of the following drugs is the safest with the greatest difference between its effect and toxic dose?

TI = 100
TI= 4
TI= 1,000
TI= 80

A

TI = 1,000

TI (therapeutic window) is plasma concentration range of a drug where
1. efficacy is high
2. adverse effects is low

Higher TI = safest drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

If given a graph and shows ED50(left of graph) and TD50(always to the right of the graph), know how to calculate TI = TD50/ED50

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which of the following types of drug would cause inactivation of a receptor with basal activity?

A

inverse agonist

an inverse agonist decreases response below basal activity (curve drops below 100)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which of the following types of antagonist inactivates the drug itself, not the receptor?

A

chemical antagonist

one drug binds to another drug making it unavailable to bind to its receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Assuming no spare receptors exist, a noncompetitive antagonist will reduce ______________ of an agonist response.

A

efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Noncompetitive antagonist

A

reduces agonist efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Competitive antagonist

A

reduces agonist potency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

physiological antagonist

A

the effect of one drug causes physiological effect opposite to action of another drug

opposing effects cancel each other out

e.g salbutamol is physiological antagonist of histamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Assuming spare receptors EXIST, a noncompetitive antagonist will reduce ____________ of an agonist response.

A

the efficacy and potency

when spare receptors exist with noncompetitive antagonist, at high concentrations, both efficacy and potency decrease.

17
Q

TRUE OR FALSE

A positive allosteric modulator activates a receptor regardless of whether an agonist is bound to the orthosteric site.

A

FALSE

PAMs differentiate/discriminate between activated and non-activated receptor states

PAMs may have a broader therapeutic window and a reduced liability for receptor desensitization and/or tolerance.

18
Q

What do agonists do?

A

activate all receptors